FHTX

Foghorn Therapeutics (FHTX)

About Foghorn Therapeutics (FHTX)

Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. It is discovering and developing a novel class of precision medicine therapeutics targeting the chromatin regulatory system in oncology. Through its scalable Gene Traffic Control product platform, the firm is systematically interrogating and drugging the chromatin regulatory system. The company was founded by Cigall Kadoch, Gerald W. Crabtree and Douglas G. Cole in October 2015 and is headquartered in Cambridge, MA.

Details

Daily high

$7.91

Daily low

$7.50

Price at open

$7.83

52 Week High

$10.25

52 Week Low

$2.70

Market cap

430.5M

Dividend yield

0.00%

Volume

90,519

Avg. volume

231,689

P/E ratio

-4.00

Foghorn Therapeutics News